An old post from Feb this year from Aureus from IV below that reminds me that maybe apebatalone is working in this trial and the post hoc anlysis from 2013 was correct for 5 point MACE,  also 6 positive DSMB reports, I guess we just hope to be highly significant 

"An average 8 percent rate is reported in our trial ongoing 
The targeted patients average 11-12 % in previous studies I believe 
So how do we get to 8% in our trial with half on Drug and half on Placebo ? 
My bet is that its something like 11-12% event rate for the half on Placebo and 4-5% 
event rate for the other half on Drug 
This would bring us to an 8% Average 
The reduction in adverse events is large if this is close to being accurate 
I may be all wrong on my opinion and welcome comments 
I believe the FDA took all this into account when accepting our Protocol on Jan 11 
to allow a two year old trial to add US sites "